These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 12717958

  • 21. Antibiotics in 30 minutes or less for febrile neutropenic patients: a quality control measure in a new hospital.
    Corey AL, Snyder S.
    J Pediatr Oncol Nurs; 2008; 25(4):208-12. PubMed ID: 18539908
    [Abstract] [Full Text] [Related]

  • 22. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients.
    Ohyashiki K.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S56-8. PubMed ID: 15250023
    [Abstract] [Full Text] [Related]

  • 23. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.
    Ramphal R.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S25-31. PubMed ID: 15250017
    [Abstract] [Full Text] [Related]

  • 24. Management of fever in neutropenic patients with different risks of complications.
    Klastersky J.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S32-7. PubMed ID: 15250018
    [Abstract] [Full Text] [Related]

  • 25. [Infections in neutropenic patients].
    Berenguer J.
    Enferm Infecc Microbiol Clin; 1995 Feb 15; 13(2):113-20. PubMed ID: 7711117
    [No Abstract] [Full Text] [Related]

  • 26. [Microbiological isolates in patients with febrile neutropenia and hematological neoplasias].
    Figuera Esparza M, Carballo M, Silva M, Figueredo A, Avilán J.
    Rev Esp Quimioter; 2006 Sep 15; 19(3):247-51. PubMed ID: 17099792
    [Abstract] [Full Text] [Related]

  • 27. Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).
    Boğa C, Bolaman Z, Çağırgan S, Karadoğan İ, Özcan MA, Özkalemkaş F, Saba R, Sönmez M, Şenol E, Akan H, Akova M.
    Turk J Haematol; 2015 Jun 15; 32(2):100-17. PubMed ID: 26316478
    [Abstract] [Full Text] [Related]

  • 28. [Prophylaxis of fungal infections in haematological patients: pro].
    Glass B.
    Dtsch Med Wochenschr; 2010 Sep 15; 135(38):1870. PubMed ID: 20842607
    [No Abstract] [Full Text] [Related]

  • 29. Clinical features of the neutropenic host: definitions and initial evaluation.
    Urabe A.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S53-5. PubMed ID: 15250022
    [Abstract] [Full Text] [Related]

  • 30. Microbiological data for patients with febrile neutropenia.
    Kanamaru A, Tatsumi Y.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S7-S10. PubMed ID: 15250014
    [Abstract] [Full Text] [Related]

  • 31. Antimicrobial prophylaxis in febrile neutropenia.
    Yoshida M, Ohno R.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S65-7. PubMed ID: 15250025
    [Abstract] [Full Text] [Related]

  • 32. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008.
    Slavin MA.
    Intern Med J; 2008 Jun 15; 38(6b):457-67. PubMed ID: 18588519
    [Abstract] [Full Text] [Related]

  • 33. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
    Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, Tanimoto M, Masaoka T, Japan Febrile Neutropenia Study Group.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S15-24. PubMed ID: 15250016
    [Abstract] [Full Text] [Related]

  • 34. The feasibility of early discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cordonnier C.
    Haematologica; 2006 Feb 15; 91(2):150a. PubMed ID: 16461296
    [No Abstract] [Full Text] [Related]

  • 35. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M, Südhoff T, Fenchel K, Egerer G, Kämpfe D, Ritter J, Franke A, Heil G, Peters G, Jürgens H.
    Wien Med Wochenschr; 1998 Feb 15; 148(21):481-7. PubMed ID: 10048176
    [Abstract] [Full Text] [Related]

  • 36. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
    Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP.
    Haematologica; 2006 Jul 15; 91(7):986-9. PubMed ID: 16757415
    [Abstract] [Full Text] [Related]

  • 37. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [Abstract] [Full Text] [Related]

  • 38. [Opportunistic infection].
    Tokimatsu I, Nasu M.
    Nihon Rinsho; 2001 Nov 15; 59 Suppl 7():205-13. PubMed ID: 11808123
    [No Abstract] [Full Text] [Related]

  • 39. Managing infections in the immunocompromised patient.
    Bodey GP.
    Clin Infect Dis; 2005 Apr 01; 40 Suppl 4():S239. PubMed ID: 15768328
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
    Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N, Kasahara S, Yamada T, Shimizu M, Nakamura M, Matsuura K, Moriwaki H.
    Am J Hematol; 2010 Nov 01; 85(11):872-6. PubMed ID: 20882524
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.